Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Grassley backs FDA “whistleblower”

Executive Summary

Senate Finance Committee Chairman Charles Grassley (R-Iowa) asks FDA in Nov. 29 letter to explain allegations that Office of Drug Safety Associate Director for Science David Graham, MD, will face compulsory reassignment or be fired for criticism of the agency at Vioxx hearing (1"The Pink Sheet" Nov. 22, 2004, p. 4). A Nov. 24 letter from Grassley calls for an HHS Office of Inspector General investigation of reports that two FDA managers sought to preemptively discredit Graham to a whistleblower protection organization. "It appears that these activities may have been coordinated by FDA management and may have involved the misuse of government resources," Grassley says...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts